High-dose atorvastatin in peripheral arterial disease (PAD): Effect on endothelial function, intima-media-thickness and local progression of PAD : An open randomized controlled pilot trial

SPRING, Silviana ; SIMON, Roger ; et al.

In: Thrombosis and haemostasis, Jg. 99 (2008), Heft 1, S. 182-189

academicJournal - print, 39 ref

Beneficial effects of aggressive lipid-lowering with high-dose atorvastatin (80 mg/day) have been demonstrated in patients with coronary and cerebrovascular disease.The impact of such a therapy in patients with peripheral arterial disease (PAD) is less known so far. Here we studied the effects of high-dose atorvastatin on brachial artery endothelial function, common carotid intima-media thickness (IMT) and local progression of PAD in these patients. One hundred of 500 patients screened with documented PAD were randomly assigned to receive 80 mg of atorvastatin daily for six months or to continue on conventional medical treatment. Ninety-six percent of patients in the control group were on standard statin treatment. High resolution B-mode ultrasonography was used to study brachial artery flow-mediated dilation (FMD), IMT and ankle-brachial index (ABI) at baseline and at six months. FMD and IMT at baseline and at six months were 4.1 (0.06-8.6) versus 5.0 (0.76 vs. 8.1) %, p=0.96, and 0.76 (0.66-0.82) versus 0.73 (0.63-0.81) mm, p=0.41, respectively, in the atorvastatin group, and 2.66 (-1.9 - 6.9) versus 3.65 (0.0-8.6)%, p=0.02, and 0.78 (0.71-0.90) versus 0.77 (0.70-0.90) mm, p=0.48, in the control group. ABI at baseline and at six months was not different in either group. LDL cholesterol was reduced from 2.53 (2.21-3.28) to 1.86 (1.38-2.29) mM (p<0.0001) in the atorvastatin group, whereas levels remained stable in the control group [2.38 (1.94-3.16) vs. 2.33 (1.82-2.84) mM, p=0.61]. Major adverse cardiovascular events occurred in 2.1 % in the atorvastatin group and 1.9% in the control group (p= 0.61). In conclusion, in this pilot trial aggressive lipid-lowering with 80 mg of atorvastatin daily for six months had no effect on brachial artery FMD in patients with PAD. IMT and ABI were also similar in patients with and without high-dose atorvastatin at six months.

Titel:	High-dose atorvastatin in peripheral arterial disease (PAD): Effect on endothelial function, intima-media-thickness and local progression of PAD : An open randomized controlled pilot trial
Autor/in / Beteiligte Person:	SPRING, Silviana ; SIMON, Roger ; VAN DER LOO, Bernd ; KOVACEVIC, Tamara ; BROCKES, Christiane ; ROUSSON, Valentin ; AMANN-VESTI, Beatrice ; KOPPENSTEINER, Renate
Link:	View record from PASCAL Archive
Zeitschrift:	Thrombosis and haemostasis, Jg. 99 (2008), Heft 1, S. 182-189
Veröffentlichung:	Stuttgart: Schattauer, 2008
Medientyp:	academicJournal
Umfang:	print, 39 ref
ISSN:	0340-6245 (print)
Schlagwort:	Cardiology, blood circulation, phlebology Cardiologie, appareil circulatoire, phlébologie Hematology Hématologie Sciences biologiques et medicales Biological and medical sciences Sciences biologiques fondamentales et appliquees. Psychologie Fundamental and applied biological sciences. Psychology Biologie moleculaire et cellulaire Molecular and cellular biology Coagulation sanguine. Cellules sanguines Blood coagulation. Blood cells Sciences medicales Medical sciences Hemopathies Hematologic and hematopoietic diseases Maladies des thrombocytes et coagulopathies Platelet diseases and coagulopathies Dérivé de la statine Statin derivative Statina derivado Enzyme Enzima Hydroxymethylglutaryl-CoA reductase Inhibiteur de l'HMG-CoA reductase HMG-CoA reductase inhibitor Inhibidor HMG-CoA reductase Inhibiteur enzyme Enzyme inhibitor Inhibidor enzima Oxidoreductases Pathologie de l'appareil circulatoire Cardiovascular disease Aparato circulatorio patología Pathologie des artères Arterial disease Arteria patología Pathologie des vaisseaux sanguins Vascular disease Vaso sanguíneo patología Artériopathie oblitérante Occlusive arterial disease Arteriopatía oclusiva Athérosclérose Atherosclerosis Ateroesclerosis Atorvastatine Atorvastatin Atorvastatina Cellule endothéliale Endothelial cell Célula endotelial Dose forte High dose Dosis fuerte Epaisseur Thickness Espesor Intima Monoxyde d'azote Nitric oxide Nitrógeno monóxido Paroi vasculaire Vascular wall Pared vascular Sténose Stenosis Estenosis Essai randomisé contrôlé Randomised controlled trial Ensayo clínico aleatorio clinical studies nitric oxide/NO stenosis
Sonstiges:	Nachgewiesen in: PASCAL Archive Sprachen: English Original Material: INIST-CNRS Document Type: Article File Description: text Language: English Author Affiliations: Clinic ofAngiology, Department of Medicine, University Hospital, Zurich, Switzerland ; Department of Biostatistics, ISPM, University Zurich, Zurich, Switzerland Rights: Copyright 2008 INIST-CNRS ; CC BY 4.0 ; Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS Notes: Blood diseases ; Molecular and cell biology

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.